The CDK4/6 inhibitors – palbociclib, abemaciclib, and ribociclib – have been approved to be used with aromatase inhibitors/fulvestrant in the setting of advanced, hormone receptor-positive breast c...
No takes yet. Share an insight, caveat, or question.
Jazieh et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: